Beam Therapeutics shareholders elect three Class II directors, ratify auditor, approve say-on-pay

Beam Therapeutics Inc.

All three director nominees (Fishman, Ho, Walsh) elected with ~39.5M votes each.
Deloitte & Touche ratified as auditor for FY2022 with 51.8M for, 3.1M against.
Advisory vote on executive compensation approved with 36.9M for, 5.7M against.
Shareholders selected every year as the frequency of say-on-pay votes; board adopts annual policy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.